<DOC>
	<DOC>NCT02583009</DOC>
	<brief_summary>This clinical study is to determine the optimum dose of PAC-14028 cream in a therapeutic confirmatory clinical study by evaluating the safety and therapeutic equivalence of PAC-14028 cream 0.1%, 0.3% and 1.0% in patients with rosacea.</brief_summary>
	<brief_title>A Study to Evaluate the Safety and Efficacy of PAC-14028 Cream in Rosacea</brief_title>
	<detailed_description />
	<mesh_term>Rosacea</mesh_term>
	<criteria>Male and female patients aged 19 70 years old Among the patients diagnosed with erythematotelangiectatic and papulopustular rosacea in accordance with the diagnostic criteria of the National Rosacea Society Expert Committee Subjects with rosacea scored 2 or more according to the Investigator Global Assessment (IGA) at screening Those who can't be diagnosed or assessed for rosacea due to the presence of trauma, tattoo, scar, excessive hairs on the facial region Those who have received a facial laser treatment within 6 weeks Those who have been administered with oral retinoid or therapeutic vitamin A within 6 months Those who have received a hormonal treatment such as estrogen within 3 months Those who have been administered with systemic antibiotics or systemic steroid formulation within 4 weeks Those who have been administered with local retinoid, local steroid and local antibiotics and local medication for the treatment of rosacea on face within 4 weeks Those who have a history of blood disorder that can have a serious effect on the clinical study Women who are pregnant, lactating or who plan to be pregnant during the clinical study period or women of childbearing potential who do not use available contraceptive methods</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>